Pharmacosmos A/S clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   Trilaciclib vs Placebo · Extensive Stage Small Cell Lung Cancer…Trilaciclib vs Placebo · Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

   Enrollment closed, study ongoing

   Also in this update: Primary and study completion pushed from Oct 30, 2027 to Feb 5, 2028

   Pharmacosmos A/S·Phase 4· NCT05874401· Registry history of NCT05874401 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

2. Minor

   Trilaciclib · Myelosupression in Subjects With Limited-stage Small…Trilaciclib · Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

   Primary and study completion pushed from Jun 2027 to Oct 31, 2027

   Pharmacosmos A/S·Phase 3· NCT07473128· Registry history of NCT07473128 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.